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Abstract In patients with unresectable colorectal liver me-
tastases (CRLM), radiofrequency ablation (RFA) might be a
good alternative, whenever possible. In contrast to systemic
therapy, the aim of RFA is to achieve complete local tumor
control in an attempt to provide long-term survival. In this
article we discuss the available evidence regarding the treat-
ment of patients with unresectable CRLM, focusing on RFA
in conjunction with modern systemic therapies. We ob-
served that the available evidence in the existing literature
is limited, and often consists of level 2 and 3 evidence,
thereby hampering any firm conclusions. Nonetheless,
RFA seems superior to chemotherapy alone in patients with
liver-only disease amenable for RFA. However, the combi-
nation of RFA and chemotherapy has been demonstrated to
be feasible and safe, lending support to the concept of RFA
followed by chemotherapy, in order to reduce local recur-
rence rates and prolong survival.
Keywords Colorectallivermetastases.Radiofrequency
ablation.Chemotherapy.Localrecurrence.Overall
survival.Progressionfreesurvival.Combinationtherapy
Introduction
One in two colorectal cancer patients will develop liver
metastases at some point during their disease [1, 2]. In
recent years significant progress has been made in the treat-
ment of metastatic colorectal cancer. Large randomized
clinical trials have been conducted showing a beneficiary
effect of different first-line and second-line chemotherapy
regimens such as capecitabine, oxaliplatin, and irinotecan,
with or without the vascular-endothelial growth factor in-
hibitor bevacizumab [3, 4]. Also, there is no doubt that
third-line treatment with epidermal growth factor inhibitors
like cetuximab and panitumumab results in prolonged sur-
vival [5–7]. Due to these regimens the median survival of
patients with metastatic colorectal cancer has improved
from 6 months [8] to more than 2 years [3, 4, 8–15].
The only potentially curative option for patients with colo-
rectallivermetastases(CRLM)issurgicalresection.Five-year
survival probabilities of up to 50% can be achieved [16, 17￿,
18].Multimodalitytreatmentincludingtheuseofneoadjuvant
chemotherapy has resulted in resectability rates of 20–25%
[19–21]. The remaining 75–80% of CRLM patients are not
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impossible, due to extensive intrahepatic metastatic lesions, or
the presence of unresectable extensive extrahepatic disease
(EHD). Without treatment these patients have a marginal sur-
vival, with only 0–2% being alive after 5 years [22, 23].
During the last decade treatment options for patients with
unresectable CRLM have evolved markedly, especially in
the era of systemic treatment and local ablative therapies. Of
those local ablative techniques, radiofrequency ablation
(RFA) is most widely used [24, 25]. In contrast to systemic
therapy, the aim of RFA is to achieve complete local tumor
control in an attempt to provide long-term survival. How-
ever, the role of RFA in unresectable CRLM is still under
debate as there are limited data comparing progression-free
survival and overall survival in unresectable CRLM patients
between systemic treatment and RFA. In this article we will
discuss the available evidence regarding the treatment of
patients with unresectable CRLM, focusing on RFA in
conjunction with modern systemic therapies.
Radiofrequency Ablation
In the last decade of the 20th century, RFA was initially
described as a procedure to treat hepatocellular carcinoma;
subsequently it was introduced as a treatment for unresect-
able CRLM [26–29]. Many studies have been conducted to
assess the effect of RFA on progression-free survival (PFS)
and overall survival (OS) in patients with unresectable
CRLM. Reported 3-year survival rates vary between 37%
and 77% [30￿￿, 31–33], while 5-year survival rates range
between 27% and 36% [30￿￿, 33] .T h e s ed a t ai n v o l v e
patients with unresectable CRLM without EHD treated with
open RFA. For percutaneous or laparoscopic RFA the out-
comes appear to be far less favorable [30￿￿].
The major problems with RFA are the high rates of intra-
hepatic and local disease recurrence. This is caused by either
the existence of intrahepatic micrometastases, or incomplete
tumor destruction by RFA, respectively [34]. Several studies
that were conducted to identify liver recurrence patterns after
RFA for CRLM showed intrahepatic recurrence rates (new
lesions) varying between 32% and 62.5% [30￿￿, 35–38].
Reported local recurrence rates (at site of RFA) also vary
widely, resulting in recurrence rates of 1.6% up to 60% [24,
30￿￿, 36, 39, 40]. It is important, however, to make a distinc-
tion between lesion-based and patient-based analyses, as the
later results in higher recurrence rates [41, 42].
The great variety in reported data is illustrated in Table 1,
revealing extensive heterogeneity in study populations, proce-
dures, and design. In addition, several studies have included
both CRLM and HCC, regardless of the entirely different
biologicalbackground and behavior ofthese entities. Needless
to say, comparisons of (disease free) survival and recurrence
rates should be viewed with great caution. Tumor size is
associatedwithlocalrecurrence;thelargerthetumorthehigher
the probability of incomplete ablation and, hence, local recur-
rence. Although newer RFA probes have resulted in more
effectiveablationwithlargerablationregions,nowadaystumor
size ≤3 cm is considered most favorable to achieve compete
tumor destruction [43, 44]. However, tumor size >3 cm is not
an absolute contraindication as effective ablation of larger
zones can be obtained by using multiple probes [45, 46].
Furthermore, RFA of lesions close to large vessels has
been questioned as the so called “heat sink phenomenon” by
the blood flow in the vessel passing the probe results in less
effective heat buildup, thereby preventing complete tumor
destruction. A retrospective study by Lu et al. actually
demonstrated that lesions in contiguity of vessels larger than
3 mm is a strong independent predictor of incomplete tumor
destruction as recurrence occurred more frequently in peri-
vascular lesions compared to non-perivascular lesions (48%
vs 7% respectively) [47]. Perivascular localization remained
an independent predictor during multivariable analysis, al-
though the study was underpowered to draw firm conclu-
sions. Moreover, the heat sink effect can be reduced by
intermittent clamping of the involved vessel [48, 49]. There-
fore, tumor localization near vessels should not be consid-
ered an absolute contraindication for RFA.
Another important factor determining local recurrence
following RFA is the type of procedure that is applied: open,
laparoscopic, or percutaneous. Plausibly, the latter involving
the fewest procedural risks and the open approach being the
most injurious one. So far, no randomized trials comparing
the open surgical approach with the percutaneous approach
have been conducted. Studies assessing the percutaneous
approach often included patients with solitary or limited
number of metastases, while studies assessing the open
surgical approach often included a higher number of (larger)
metastases per patient. The currently available evidence
regarding survival demonstrates superior outcomes follow-
ing the open approach compared to the laparoscopic and
percutaneous procedures [24, 30￿￿, 50–52]. Also, local re-
currence rates are lower in the open surgical group com-
pared with the percutaneous group (6–16% [31, 32, 39, 50]
versus 17–59% [50, 53, 54], respectively). However, in the
absence of data demonstrating improved survival outcomes
when comparing similar groups of patients, the benefits of
improved local control observed with the open approach
must be weighed against the morbidity and cost associated
with it . In addition, from the perspective that chemotherapy
in combination with RFA debulking is reasonable, the risk
of leaving behind a small number of tumor cells with the
percutaneous approach may likely not be clinically detri-
mental in most cases in which this occurs. Moreover, if the
lesion location is such that a local recurrence can be sal-
vaged by subsequent resection, percutaneous RFA would
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132 Curr Colorectal Cancer Rep (2012) 8:130–137seem reasonable provided that state-of-the-art CT guidance
is available.
A noteworthy benefit of RFA is the possibility to perform
repeated procedures. Several prospective cohort studies
have shown that repeat procedures in patients with early
(local or intrahepatic) recurrence after RFA results in similar
survival rates as patients treated with RFA without intra-
hepatic recurrences [41, 49, 55￿]. No doubt that introduction
of percutaneous RFA application has widened the possibil-
ities for repeated RFA. Therefore, each patient showing
disease recurrence should be carefully evaluated for this
option [30￿￿, 55￿].
So far, RFA has only been proposed as a potentially
curative treatment option for selected patients with CRLM
without EHD [56￿￿]. However, the group of Siperstein and
Berber published two prospective cohort studies (234 [54
with EHD] patients and 135 [40 with EHD] patients, re-
spectively) investigating the role of RFA in patients with
EHD [25, 53]. Siperstein et al. observed similar median OS
in patients with and without EHD at the time of RFA (20 vs
25 months, respectively, NS). Berber et al. performed a
multivariable analysis which showed no negative effect of
EHD on survival. Moreover, they argued that in 70% of the
deceased patients death was contributed to their intrahepatic
disease progression. Hence, it was proposed that debulking
of liver metastases by RFA in patients with EHD might be a
helpful strategy. However, we believe that the presence of
EHD in both studies did not result in a statistically signifi-
cant negative effect (maybe due to underpowered study
designs), and cannot be interpreted as results in favor to
perform RFA in patients with EHD. In contrast, two studies
by Gillams et al. and Machi et al. prospectively analyzed
309 and 100 patients with unresectable CRLM, respectively,
in order to assess the influence of concomitant EHD on
survival in patients with CRLM treated with RFA. Both
studies found a significant negative effect on survival com-
pared with patients without EHD (P<0.05), especially for
EHD other than lung metastases [57￿, 58]. Based on the
available evidence RFA should not be advised in patients
with concomitant EHD.
Taken together, there is accumulating evidence that RFA
of CRLM can result in long-term survival in selected cases.
Optimal results may be achieved with an open surgical
approach or CT-guided percutaneous procedures, in patients
without EHD, in lesions <3 cm, while the procedure should
be performed by experienced physicians [56￿￿].
RFA, Chemotherapy, or Combined Treatment
The debate is still ongoing on whether patients benefit most
from RFA, systemic treatment, or a combination of the two.
Reported OS following open RFA appears to be superior to
that of chemotherapy (median overall survival 30–31 vs 20–
23 months, respectively) [9, 32, 59￿, 60]. However, several
issues need to be addressed. First, most studies on RFAwere
conducted in patients with unresectable metastases confined
to the liver, while all chemotherapy studies investigated
patientswithsystemicdisease,oftenincludingextensiveintra-
hepatic disease and EHD. Also, other baseline characteristics
such as tumor size and number differed between the RFA
studies and the systemic treatment studies. Furthermore, sev-
eral RFA studies combined data of patients with metastases
from different primary sites. Moreover, some of the RFA
studies included patients receiving RFA alone as well as
patients who received a combination of RFAwith either pre-
treatment or post-treatment chemotherapy, thus hampering
interpretation of the data due to induced heterogeneity.
In one of the rare comparative studies published hitherto,
Ruers et al. investigated RFAversus systemic therapy in 201
patients harboring CRLM without EHD initially scheduled
for surgery [32]. During laparotomy patients were allocated
to one of three treatment arms: resection if feasible, local
ablation therapy (sometimes combined with resection if
resection [alone] was not feasible), or systemic treatment if
neither of these procedures were possible. Baseline charac-
teristics between the local ablation and systemic therapy
groups were similar. Five-year OS was not significantly
different between both groups, with 27% of the patients still
alive in the local ablation group and 15% in the chemother-
apy group. Median OS and DFS were 31 and 9 versus 26
and 0 months, respectively. If this is truly a significant
difference in median overall survival, the difference is quite
small and it would require substantially larger patient
cohorts to confirm significance. Furthermore, the observed
median OS of 26 months in the chemotherapy group is
rather high when compared with other chemotherapy trials,
which might be explained by the predominant inclusion of
patients with CRLM confined to the liver. Abdalla et al.
observed a significant (7 months) survival benefit for RFA
compared to systemic therapy in CRLM patients [31]. This
finding was based on data from consecutive series of 418
selected patients identified in their prospectively assembled
database. Although the survival curves were converging at
almost 55 months of follow up, 3-year survival rates were
almost twice as high for patients receiving RFA compared to
patients receiving chemotherapy. Thus, with RFA, the ma-
jority of people live longer compared to patients receiving
chemotherapy, but eventually the survival curves of both
groups will approach zero. However, important to mention
is that the allocation to the different treatment groups was
not random. Rather, it was determined by the extent of
tumor burden determined intraoperatively, meaning the che-
motherapy patients most likely had a higher tumor load.
Nonetheless,asthe major problemregarding RFAinvolves
the highrateofdisease recurrence, it seems reasonabletoseek
Curr Colorectal Cancer Rep (2012) 8:130–137 133for a combination treatment of RFA with systemic therapy.
Further ground for such combination comes from preclinical
studies where micrometastases surrounding the ablated region
were recently shown to be triggered toward a more aggressive
growth pattern following RFA so that combination with sys-
temic therapy and/or hypoxia-activated prodrugs appears jus-
tified [61, 62]. Such combination strategies could be
envisioned in two ways: 1) debulking tumor mass by RFA
toreducethetumorloadneededtotreatwithsystemictherapy,
or 2) downstaging with systemic therapy followed by RFA of
the remaining lesions. Literature regarding this topic is sur-
prisingly scarce. Knudsen et al. evaluated the long-term sur-
vival of 36 patients treated with RFA for initially unresectable
CRLM down-staged by systemic chemotherapy [63]. Patients
w i t hE H Dw e r ee x c l u d e df r o mt h i ss t u d y .T h e yo b s e r v e da
median OS of 39 months with a 5-year survival rate of 34%.
Oneshouldnotethatthisstudyselectedpatientsbasedontheir
responsiveness to systemic therapy, thereby introducing sig-
nificant bias. Nonetheless, the reported 5-year disease-free
survival of 14% is substantial.
Siperstein et al. conducted a prospective cohort study, in
which 234 consecutive patients undergoing 292 RFA pro-
cedures for unresectable CRLM were evaluated [25]. The
majority of these patients received systemic therapy prior to
RFA and of those patients, 80% were poor or non-
responders. In these patients median OS following RFA
was 24 months, or 32 months from time of diagnoses as
proposed by the authors. This is in sharp contrast to the
12 months from time of diagnosis for patients who are
unresponsive to systemic therapy and not subsequently
treated by RFA [53]. As the authors based this control group
on data from 1999, it may be more justified to compare their
data with the more recent chemotherapy studies mentioned
earlier, which described an OS of up to 22.6 months [9, 64,
65]. Even though randomized data are non-existent, this
would still represent a major improvement, with a 10-
month benefit for patients receiving RFA following che-
motherapy. Based on this study it would appear that
RFA might have a role in controlling local disease for
patients with unresectable CRLM who proved unrespon-
sive to chemotherapy.
Regarding the question whether there is a role for tumor
debulking by RFA followed by systemic treatment, data are
limited. In 2007, Frezza et al. published a pilot study on 11
patients who underwent “debulking” by RFA of liver me-
tastases of different origin prior to chemotherapy. With a
mean follow-up of 22 months, none of these patients died
from their disease while only two developed tumor recur-
rence [66]. In the aforementioned study by Siperstein et al.,
a significantly better OS of 28 months was observed in
patients receiving chemotherapy following RFA, compared
to 19 months for RFA alone [25]. However, as this was a
purely observational finding and not the primary focus of
the study, the authors were justifiably cautious to draw any
conclusions. They argued that the observed effect might
have been caused by selection bias by reserving “adjuvant”
chemotherapy for patients responsive to RFA. Due to the
limited number of patients and retrospective nature of the
study, it is impossible to draw any firm conclusions from
these studies.
The only prospective randomized trial assessing this top-
ic is the CLOCC trial [67￿￿]. In this randomized phase II
trial 119 patients with <10 unresectable liver metastases
without EHD were randomly assigned to either systemic
treatment, or the combination of RFA followed by systemic
treatment. In the chemotherapy-alone group 30 months OS
was 57.6% compared to 61.7% in the combination group.
However, this difference did not reach statistical signifi-
cance, which may in part be explained by the much higher
than expected observed survival data for patients treated
with chemotherapy alone. Median PFS, however, was sig-
nificantly different between both study arms. Median PFS in
the combined treatment group was 16.8 months compared to
9.9 months in the chemotherapy-alone arm. As the random-
ized phase II design of the study was underpowered to
detect differences in OS, the authors concluded that RFA
plus systemic treatment results in significant benefit in PFS
without significant benefit in OS at 30 months, and that
longer follow-up should be awaited. Meanwhile, one cannot
ignore a 30 months OS of 61.7% as an excellent result
which, so far, has not been demonstrated in other studies.
Taken together, the best available evidence points toward a
benefit for the combination strategy using RFA and chemo-
therapy, although convincing proof is still lacking.
In an attempt to delineate whether the timing of chemo-
therapy treatment (pre-RFA or post-RFA) affects patient out-
come, Sgouros et al. recently reported a prospective study
comparing the use of RFA before or after chemotherapy in
patients with unresectable CRLM [68]. Patients received ei-
ther FOLFIRI before RFA, or FOLFOX or FOLFIRI post-
RFA. Unfortunately, the total of included patients was low
(n031).Moreover,patientswerenotrandomizedbutallocated
to one of the treatment schemes on the basis of tumor size,
withpatientsharboring larger tumorsstartingwith chemother-
apy. In addition, 50% of the patients starting with chemother-
apy did not receive RFA due to disease progression. Although
PFS and OS did not differ significantly between the groups
(13 and 21 months vs 10 and 21 for the pre-RFA and post-
RFA groups, respectively), the study limitations render any
firm conclusions problematic.
Apart from survival rates, a comparison can be made
betweenRFA and systemic therapy regarding toxicityprofiles
and quality of life. Ruers et al. showed that patients receiving
chemotherapy following laparotomy demonstrated a signifi-
cantly lower quality of life compared to RFA following lapa-
rotomy [32]. Moreover, as disease-free periods can be
134 Curr Colorectal Cancer Rep (2012) 8:130–137achieved with RFA, patients may be provided time without
toxicity. This is in sharp contrast to patients undergoing repet-
itive sessions of systemic therapy.
Conclusions
The level of evidence emanating from the existing literature
hampers any firm conclusions. Nonetheless, it would appear
that RFA may prove superior to chemo alone in patients
with liver-only disease amenable for this modality. Also, the
combination of RFA and chemo has been demonstrated to
be feasible and safe, lending support to the concept of RFA,
whenever possible followed by chemotherapy.
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